Symbiotec Pharmalab’s ₹1,757 crore IPO is open for subscription from August 24 to August 27, 2026. While brokerages like Geojit highlight its global leadership in steroid APIs, investors should weigh this against a large offer-for-sale component and recent regulatory inspections.
Symbiotec Pharmalab Limited has opened its Initial Public Offering (IPO) today, August 24, 2026, with the subscription window set to remain open until August 27, 2026. The company, which specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and operates as a Contract Development and Manufacturing Organisation (CDMO), has set a price band of ₹938 to ₹988 per share for this issue.
The total IPO size stands at ₹1,757 crore. This includes a fresh issue of shares worth ₹150 crore, which the company intends to use for its business operations, and an Offer for Sale (OFS) of ₹1,607 crore. In an OFS, existing shareholders sell their shares to the public, meaning the proceeds from this portion go to the selling shareholders rather than the company’s own balance sheet.
Geojit Financial Services has initiated coverage with a 'Subscribe' rating, pointing to the company's established position in the pharmaceutical market. Symbiotec maintains a significant global presence, holding a 38.2% volume-based market share in corticosteroid APIs and a 23.8% share in steroidal-hormone APIs as of fiscal year 2026. The company’s portfolio includes over 60 APIs that serve critical medical needs in areas such as respiratory health, oncology, dermatology, and gynaecology.
While the company’s market share is notable, prospective investors should also consider several risks highlighted in the company’s filings. A primary monitorable is the outcome of a recent US FDA inspection that took place on August 14, 2026. Any adverse findings from this inspection could affect the company's ability to export to key markets or require remedial investments. Additionally, the company faces business concentration risk, as a significant portion of its revenue is derived from a limited set of products and customers.
Financially, Symbiotec Pharmalab reported a total income of ₹872.26 crore and a net profit of ₹109.90 crore for the fiscal year 2026. At the upper end of the price band, the IPO is valued at a Price-to-Earnings (P/E) multiple of approximately 57.81 times its projected fiscal year 2026 earnings. Investors may also want to note that the large size of the OFS relative to the fresh issue means that a substantial part of the investment is not directly contributing to the company’s capital expansion.
The equity shares are proposed to be listed on the BSE and the NSE, with the tentative date for listing set for September 1, 2026. Market participants will likely watch for the subscription numbers over the next three days to gauge demand, as well as any official updates regarding the recent FDA inspection status.